David P. Kao

May 3, 2024 | medrxiv.org | David P. Kao |James Martin |Christina L. Aquilante |Elise L Shalowitz

The authors have declared no competing interest. This study did not receive any funding. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The raw data used in this study is publicly available at https://open.fda.gov/data/faers/).

May 2, 2024 | medrxiv.org | Peter Hyson |David P. Kao

The authors have declared no competing interest. This study was funded by the NHLBI: K08 HL125725 (PI: Kao), L30 HL110124 (PI: Kao); and by the American Heart Association: 171G33660301 (PI: Kao)I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Nov 3, 2023 | mdpi.com | Monica Bianchini |Christina L. Aquilante |David P. Kao |James Martin

1. IntroductionPharmacogenomics, a component of precision medicine, leverages patient-specific genetic information to inform medication prescribing with the goal of increasing effectiveness and decreasing adverse effects. Pharmacogenomic medications are medications for which there is an established genetic association that may impact therapeutic management.